Select Transactions
|
| Sale of Stock and Conditional Sale to |
|
|
$215 million + CVRs
February 2019
|
|
| Debt Recapitalization and Acquisition of NextWave Pharmaceuticals from |
|
|
$125 million
September 2018
|
|
| Majority recap by |
|
|
$125 million
April 2019
|
|
| Acquisition of generics business of |
|
|
$1.05 billion
June 2017
|
Torreya is a leading strategic M&A advisor to global life sciences companies. MORE
Torreya is one of the most active financial advisors on pharmaceutical-product asset sales. MORE
Torreya’s Capital Markets team arranges debt financings, royalty monetizations, IPOs, and private equity recapitalizations. MORE
Torreya is a leading advisor on pre-commercial and commercial-stage licensing deals. MORE
Creating Value Through China Partnering
Record Activity Level in Pharma In-Licensing in China
Torreya’s report provides an overview of burgeoning market for in-licensing of pharmaceutical products into China. Key points include:
- Thus far, in 2018, we have seen more than five deals a month announced, on average. In contrast, five years ago (2014) there was roughly one deal a month announced.
- The value of licensing activity in China has also risen.
- Protection of intellectual property has improved substantially.
Click Here for Report Executive Summary | Click Here for Full Report